INTELLECTUAL PROPERTY PORTFOLIO FOR TREATMENT AND MANAGEMENT OF PAIN (SF00-02, SF03-041, SF03-078, SF04-041)

UCSF has amassed an intellectual property portfolio in the area of potent analgesic combination drug therapies for the relief of pain, particularly neuropathic and inflammatory pain. Our investigators have shown that the analgesic effects of partial agonist kappa-opioid agonists can be enhanced by addition of either opioid antagonists or antipsychotic/neuroleptic agents. These drug combinations have been tested and validated clinically and in animal models of inflammation and peripheral neuropathy. This portfolio would provide a company with proprietary pharmaceutical compositions and their method of use for clinical treatment and management of pain.

ADVANTAGES:

• Synergistic effects for some drug combinations.



• Low drug dosage to mediate pain.



• Fewer side-effects compared to m-opioid analgesics or narcotics (morphine)



• Less abuse potential

INTELLECTUAL PROPERTY: UCSF has an issued patent (US Patent No. 6,525,062) claiming method of use of specific pharmaceutical compositions comprised of kappa-opioid agonists and antagonists for the treatment of pain. Foreign patent rights are also available and are currently being prosecuted. Subsequent divisional and continuation applications have been filed claiming priority of the parent issued patent. These applications are directed towards composition of matter for kappa-opioid agonist and antagonist pharmaceutical formulations, expanded method of use and method of administration of such formulations (Application No. 10/327,508, 10/359,921, 10/458,499).

UCSF has filed a patent application (Application No. 10/734,308) that expands the scope of the issued patent 6,525,062 to include broader formulation ranges and additional kappa-opioid compounds. Foreign patent rights are also available and are currently being prosecuted overseas.

UCSF has also filed a patent application (Application No. 60/592,418) claiming methods of use of pharmaceutical compositions comprised of kappa-opioid agonists with anti-psychotic or neuroleptic agents with antagonist activity at sigma and/or dopamine receptors for treatment of pain.

References:
Gear, R.W. et al. (2003) Dose ratio is important in maximizing naloxone enhancement of nalbuphine analgesia in humans. Neurosci Lett. 351(1): 5-8.
Khasar, S.G. et al. (2003) Absence of nalbuphine anti-analgesia in the rat. Neurosci Lett. 345(3): 165-168.
Schmidt, B.L. et al. (2003) Response of neuropathic trigeminal pain to the combination of low-dose nalbuphine plus naloxone in humans. Neurosci Lett. 343(2): 144-146.
Gear, R.W. et al. (1999) The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain 83(2):339-345.
Levine, J. et al. (1988) Potentiation of pentazocine analgesia by low-dose naloxone. J Clin Invest 82(5): 1574-1577.

If you would like to receive further information about this technology and potential licensing opportunities, please contact:

Sunita Rajdev, Ph.D.
Licensing Officer
Phone: (415) 353-4470
Fax: (415) 348-1579
Sunita.rajdev@ucsf.edu

Reference: OTM Case #SF00-02, SF03-041, SF03-078, SF04-041